Towards domestication of Jatropha curcas

Jatropha curcas L. attracts a lot of interest as a biofuel crop, triggering large investments and rapid expansion of cultivation areas, and yet, it should still be considered as a (semi-)wild, undomesticated plant. To use the full potential of Jatropha and to support further expansion and systematic selection, breeding and domestication are a prerequisite. This review reveals and identifies gaps in knowledge that still impede domestication of Jatropha. Prebreeding knowledge is limited. In particular, the regeneration ecology and the degree of genetic diversity among and within natural populations in and outside the center of origin are poorly studied. There is only a limited understanding of the Jatropha breeding system and the effect of inbreeding and outbreeding. This review presents all currently available and relevant information on the species distribution, site requirements, regeneration ecology, genetic diversity, advances in selection, development of varieties and hybridization. It also describes possible routes to a better Jatropha germplasm, gives recommendations for tackling current problems and provides guidance for future research. We also discuss the participatory domestication strategy of Jatropha integration in agroforestry. © 2010 Future Science Ltd.info:eu-repo/semantics/publishe

Importance of Baseline Prognostic Factors With Increasing Time Since Initiation of Highly Active Antiretroviral Therapy: Collaborative Analysis of Cohorts of HIV-1-Infected Patients

Background: The extent to which the prognosis for AIDS and death of patients initiating highly active antiretroviral therapy (HAART) continues to be affected by their characteristics at the time of initiation (baseline) is unclear. Methods: We analyzed data on 20,379 treatment-naive HIV-1- infected adults who started HAART in 1 of 12 cohort studies in Europe and North America (61,798 person-years of follow-up, 1844 AIDS events, and 1005 deaths). Results: Although baseline CD4 cell count became less prognostic with time, individuals with a baseline CD4 count 350 cells/μL (hazard ratio for AIDS = 2.3, 95% confidence interval [CI]: 1.0 to 2.3; mortality hazard ratio = 2.5, 95% CI: 1.2 to 5.5, 4 to 6 years after starting HAART). Rates of AIDS were persistently higher in individuals who had experienced an AIDS event before starting HAART. Individuals with presumed transmission by means of injection drug use experienced substantially higher rates of AIDS and death than other individuals throughout follow-up (AIDS hazard ratio = 1.6, 95% CI: 0.8 to 3.0; mortality hazard ratio = 3.5, 95% CI: 2.2 to 5.5, 4 to 6 years after starting HAART). Conclusions: Compared with other patient groups, injection drug users and patients with advanced immunodeficiency at baseline experience substantially increased rates of AIDS and death up to 6 years after starting HAART